secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001104659-24-089065
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin posts Q2 net loss of $2.0M; cash $12.6M; expands Netherton trials internationally
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities of $12.6M as of June 30, 2024; expected to fund operations into late 2025.
- Net loss for Q2 2024 was $2.0M ($2.1M in Q2 2023); six-month net loss $4.3M ($4.7M in prior year).
- Signed research agreement with University College Cork for topical rapamycin formulations using dissolvable microneedle technology.
- Expanded Netherton Syndrome clinical trials to international sites starting with Saudi Arabia and EU.
- Announced plans to initiate clinical study in Peeling Skin Syndrome, first site and patient identified.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465924089065/0001104659-24-089065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465924089065/tm2421595d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-089065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer